Latest News



July 27, 2018 0

Whether you’re new to the DTC pharma space in the US, or an industry veteran, what you need to know to stay ahead.

The advertising of prescription drugs on TV and in magazines is a uniquely American phenomenon. Turn on the news or flip through a magazine and you’re likely to notice a pharmaceutical commercial or ad. In fact, prescription drugs are now among the top 10 most advertised product categories in the US.

In the 15 years I’ve helped pharma brands forecast and test their direct-to-consumer (DTC) ad campaigns, I’ve seen a shift in the content. Where ads originally focused on drugs for widespread medical conditions (e.g. high cholesterol, depression), today’s campaigns address health problems suffered by much smaller populations, such as Crohn’s Disease and lung cancer. But that’s just one example of how the DTC pharma market has evolved in the US.

My SKIM healthcare colleagues and I recently attended the DTC National Conference in Boston to explore the industry’s latest trends and innovations. Here I’m sharing our top three takeaways from the DTC conference:

1. The Promise & Pitfalls of the 6-Second DTC Ad

Often referred to as “bumper ads,” the 6-second YouTube ad is a popular option for consumer marketers. But can these work for pharma brands? With their long length, complex messages, and side effects requirements, pharma DTC commercials may seem like unlikely candidates for this media.

However, 6-second DTC ads are not only plausible; their utilization is expected to grow. While the 6-second length is prohibitive for branded DTC ads with product claims and side effects, “reminder ads” are compatible with this short format.

What’s the ideal scenario for this type of media buy?

Woman on tablet

Since reminder ads only emphasize the drug brand name and contain no information about product benefits or side effects, we recommend their use in supplementing larger, branded campaigns. Brands spending at least $50 million in annual advertising will see most success with bumper ads. Since these 6-second ads typically employ the same creative look and feel as the longer commercials, they can aid viewer recall. However, without that level of ad spend, these 6-second DTC reminder ads are risky as they lack context and meaning when they’re seen by patients who haven’t been reached by the associated branded campaign.

2. Consider Addressable TV for Advanced Targeting

Successfully targeting and reaching the intended audience has always been a challenge for pharma marketers planning DTC campaigns. The population of patients who are eligible for the medication may be relatively small, meaning that a high percentage of advertising impressions are “wasted” on viewers who have no interest in the advertised product and will never be candidates for treatment.

“Addressable TV” is a digital innovation that allows marketers to target specific households using algorithms based on demographic and geographic data, similar to digital video. With nearly 50 million US households ‘addressable’ via cable set-top boxes, advertisers can now identify those homes whose members have a greater likelihood of having the medical condition that is treated by their pharmaceutical product.

Couple watching TV

Take as an example osteoarthritis, a medical condition that primarily affects an older demographic. Marketers can use Addressable TV to advertise an osteoarthritis drug directly to households with individuals 60+ years old vs. those with younger viewers who may be tuned in to the same programming next door.

When we work with pharma brands to forecast the impact and ROI of DTC campaigns, we model the awareness-generating ability of Addressable TV differently than we model traditional television. Current industry analysis indicates that Addressable TV is more effective; we will see if this trend remains evident as more and more data becomes available.

3. Explore Ad Concepts with Real Patients vs. Actors to Enhance Campaign Authenticity

Pharmaceutical DTC campaigns are sometimes criticized for using actors who don’t resemble actual patients, presenting an unrealistic depiction of the medical condition. Perhaps with this criticism in mind, some advertisers have opted for real patients in campaigns instead of actors.

“Before and after” photos are a staple of advertisements for dermatological medications. These photos become more convincing if real patients are depicted. Not only does the portrayal of the true efficacy of the medication become more accurate, the authenticity of the message is enhanced.

Nervous to ditch the actors? In our pharma DTC concept testing research, patient groups evaluate different ads and rate them according to standard metrics, such as their expected likelihood of asking their doctor to prescribe the medication. Patients can often sense when an advertisement is inauthentic and the message is more likely to resonate when authenticity shines through.

 

This article is republished with permission. Click here to read the original posting.

Fred Church


May 29, 2018 0

If I have heard it once, I have heard it a thousand times: organic marketing on Facebook is dead. Pay-to-play, experts say, is the only way to really reach desired audiences. Regardless of industry, this has been the overall takeaway.

This clarion call has only gotten louder since Facebook announced in January that it would further prioritize content from friends and family on users’ News Feeds (see here for Facebook’s current commercial). This effectively makes it nearly impossible for brands’ organic content to rank high enough to be seen and forces them to spend more on paid ads.

Well, to paraphrase Mark Twain, reports of the death of organic Facebook marketing have been greatly exaggerated. The first step to successfully fighting off that organic content death knell is identifying what connects Facebook users to those friends and family whose content will be prioritized: relationship.

Relationship Required for Effective Organic AND Paid

The challenge – for brands, at least – is that Facebook feeds effectively reflect what we want to do and see in real life. As users, we are interested in what our family members are up to; get excited about friends’ baby announcements; and engage with people on their opinion about new movies.

All of these things are built around our unique relationships, and, to be blunt, reading a post from a pharmaceutical campaign doesn’t typically rise to that same level. In general, a brand’s priorities are not about the Facebook user; they’re about the brand. It’s possible for a brand to establish a trustworthy relationship with users, but it requires commitment.

What exactly do I mean when I talk about a relationship on Facebook? Despite Facebook being a technology platform, the relationships are still human. They can be emotional, educational and supportive. Ultimately, two-way conversations are the cost of entry for a true relationship.

If a brand creates content that allows for meaningful conversation and has a clear benefit to users, it will start to receive likes, comments, and shares. As that brand’s content consistently receives engagement, Facebook will increasingly deem this a real relationship and make it more likely for that content to appear organically in the feed.

Organic growth will slowly occur as people share posts with their friends, who then share the posts with their friends. Eventually, brands will begin to build relationships via these people who are connected by shared interests. For those with patience, there is power in organic growth.

Of course, for those with less patience who want to reach more people quickly, it then is necessary to pay to promote content. However, a marketer with good Facebook user relationships – and, as a result, successful organic content – won’t need to pay as much. Facebook understands the value of relationships to users, as well as the value of those relationships to the relevance of the entire platform. Therefore, it doesn’t want to waste feed real estate – no matter how much brands pay them – on poor relationships.

How Most DTC Marketing Content Falls Short

Unfortunately, pharmaceutical brands don’t necessarily have the infrastructure to create authentic, relationship-building content that truly meets patients where they are. For a multitude of reasons – including risk, regulatory issues, and the lack of a core competency in creating content – it is nearly impossible for marketers to engage in open-ended conversations via social and digital platforms, including via unbranded campaigns. This reality limits the organic potential.

Marketers of unbranded campaigns often create generic content relevant to a perceived majority of people living with a specific condition or focused around a celebrity with some relationship to that condition.

However, not every person has the same experience with a specific condition. From symptoms to family life dynamics, people are as diverse as their feeds. Regardless, pharma brands spend a lot of money and resources forcing generic content into people’s Facebook feeds that doesn’t truly foster a relationship. Making matters worse, it creates a vicious cycle of overpaying.

What Marketers Need to Do

As marketers, we need to create a range of personal content that speaks to people at various stages of their journeys. This content must encompass a wide variety of emotional, educational and comprehension levels. For example, it’s important to include posts about clinical trials for those who are more inquisitive and proactive about treatments along with lifestyle articles about how tough it can be to wake up in the morning for the newly diagnosed.

The intent behind this is not simply to increase reach, which it still does. On a greater scale, it establishes that a brand is willing to understand where people are in their patient journeys, as well as the information, resources, and conversations they need. This increases the likelihood that a Facebook user with a specific condition will find content relevant and worthy of engagement. That engagement then makes it more likely to push that marketer’s content toward the top of that user’s feed.

There are two major obstacles here. First, it’s not easy to just start creating relatable posts, engaging around it on Facebook, and assuming it will have impact as organic content. Marketers need to be fully committed to having a two-way relationship with people and everything that entails.

Second, as mentioned previously, pharmaceutical brands can only do so much on social and digital channels, due to the regulatory environment. Therefore, the first step is to get into the mindset of “meeting people where they are.” This is done by being open to and then creating promotional campaigns, tools, and ads that show the brand understands various aspects of the patient journey, as opposed to creating a single ad or promoted post that might only be relevant to a subset of people with a condition.

However, to truly get the desired organic reach on Facebook, brands should invest in the necessary resources to understand people’s needs. The best way to do this is by partnering with companies adept at listening to relevant condition-specific conversations, moderating engagement, and adapting messaging. In short, these partnerships are the relationships brands need to create and maintain meaningful relationships on Facebook.

David Shronk


May 29, 2018 0

In an ever-changing pharma environment staying connected is vital. Amidst regulatory challenges and uncertainty of new channels, the pharma industry is beginning to embrace social media to empower patients and healthcare providers. Social platforms are uniquely designed to support patient and provider needs perhaps more directly and efficiently than traditional channels. Social technologies can be leveraged to support patient engagement, ultimately leading to healthier patient outcomes.

 

Karen Weber


May 29, 2018 0

Sponsored Content

PatientPoint had the honor of sponsoring the Top 25 DTC Marketers and Hall of Fame awards at last month’s DTC National. During Hall of Fame inductee Christine Sakdalan’s passionate acceptance speech, one of her quotes really stood out, as it touched on some very relevant topics within our industry. She said: “More than ever, we have the great privilege and responsibility in healthcare to positively impact people’s lives. To make a meaningful difference in patient outcomes, we must purposefully lead with compassion and empathy, engage in relevant dialogue and foster partnership across the healthcare ecosystem.”

These values that Christine noted need to be at the forefront of decision-making during planning season. Lead with empathy. Engage in meaningful dialogue. Foster partnership. If your marketing strategy is built on these foundational tenants, and delivers relevant messaging to the patient at the time he or she needs the information the most, a positive impact is a near guarantee.

I see proof of this daily as I work with our client partners to create plans that enable their brands to be a part of the important discussions between patients and physicians. Sharing compelling testimonials, savings offers, clinical trial results and other similar information in the doctor’s office offers patients the guidance and empowerment they need at this time, making your brand a true partner to not only patients but their healthcare providers as well.

With all the news about consumers losing trust in brands today, it seems now more than ever is the time we collectively focus our efforts on what truly matters the most—the patient. This may involve a change from your tried and true marketing tactics, instead thinking outside the box to focus more on the channels, like point of care, that enable you to truly connect with patients and physicians and, as Christine so well noted in her speech, make a meaningful difference in patients’ lives. PatientPoint can help you do just that.

 

Linda Ruschau


May 29, 2018 0

The word “cancer” has become a household word, used by cancer centers, drug manufactures and the non-profit community in aggressive and extensive DTC marketing initiatives. But, historically, marketing cancer products directly to consumers rarely (if ever) happened; it was one of those areas that was deemed to be “pushing it too far.” What has contributed to this significant shift? And what role does DTC advertising truly play today? As the cancer conversation continues to grow across national television and other channels, we believe understanding this shift is imperative. As such, we initiated research to uncover insight into the impact and role of today’s DTC efforts in this once taboo category. Our work included a combination of quantitative and ethnographic research with cancer patients and their oncologists.

We recently had the privilege of presenting our findings to an audience of industry peers and colleagues at the 2018 DTC National Conference in Boston and, not surprisingly, our presentation hit a nerve. In fact, during the presentation, one audience member spoke out, sharing his experience with a stage 4 cancer diagnosis and how he could directly relate to the research findings we were presenting. This powerful moment was followed by a few others, including multiple audience members approaching us after our presentation to share their personal cancer anecdotes. We were moved by this level of audience engagement, and, of course, thrilled that our content had transcended professional relevance to make personal connections with people who had themselves experienced cancer. What follows is a summation of some of the more salient points from our presentation.

We are in the age of consumer-driven, patient-centered healthcare. New tools are empowering patients and shifting US consumer expectations. Take the Internet, for example, easily the broadest and most common tool…

  • 70% of people use the Internet to figure out what condition they may have before visiting the doctor1
  • 52% use the Internet to understand what they need to discuss with the doctor1
  • 84% use the Internet to learn about treatment options after receiving an initial diagnosis1
  • 61% use the Internet to learn about treatment choices and side effects1

Information sources proliferate. Think about it: there is so much available, both online and offline, from government agencies, manufacturers, pharmacy services, health plans, hospitals, cancer centers, non-profit organizations, clinical trial recruitment, advocacy groups, support services, and even social media.

As such, healthcare has become an everyday conversation. And this includes the once taboo c-word, cancer. Can you remember a time when you would hear a friend or family member whisper that someone has cancer? Now, you hear people talk about it openly at home, at work, and even at the local market or Starbucks.

The Mighty is a social media platform where consumers create message boards and share content. Within the platform, there are about 40,000 people following the broader topic of cancer today, with about 50 separate cancer communities. This demonstrates exactly what we were saying—people are no longer afraid to talk about cancer. Patients and care partners seek out these communities for emotional support, education, information, and often for some much needed self-expression.

In 1996, when DTC advertising began with blockbuster drugs like Lipitor and Claritin, there was a total spend of $555 million behind prescription medications. It was a market dominated by allergy, cholesterol, migraine, and dermatology treatments. At that time, and even just a few years ago, DTC about cancer treatments wasn’t a thought. However, DTC today reflects a different mix for a different time. Every time you turn on the TV, there’s a good likelihood you’ll see a DTC ad focused on a cancer treatment. This includes some great work from brands like Ibrance, Keytruda, Neulasta, and Opdivo. Not surprisingly, $504 million was spent on oncology DTC in 2017 alone. Yes, that is close to the whole DTC spend across all categories back in 1996. And the cancer conversation is not limited to just advertising. Cancer has become a topic in mass media and news environments as well. From Robin Roberts’ very public cancer journey on TV, Time Magazine’s cover pages on how to cure cancer, and even US News and World Report ranking the top cancer hospitals in 2017-18, there is no shortage of daily headlines about cancer.

So why the shift?

  • Talking about cancer is no longer taboo.
  • Consumer expectations of cancer have changed. For example, there is now an understanding and expectation that—in many cases—you will survive a cancer diagnosis. In addition, treatments can go on for an extended period of time.
  • The information age has helped to drive shared decision making.
  • There’s an increased level of patient involvement in the physical treatment. In fact, from targeted oral therapies to patches, some patients can now engage in chemotherapy at home.
  • There is increased competition and “noise” in the cancer space, from the proliferation of treatment options, to discussions of rising healthcare costs, and the rise in the number of interested and invested parties (i.e., health systems, advocacy, etc.).

Yet, despite all of these changes, people still lack a voice when it comes to cancer conversations with their oncologists. With our 20 years of experience in ethnographic in-office dialogue research, we have recorded well over 4,000 visits, with over 400 in oncology. That, combined with the over 800 post-visit interviews with oncology patients and their oncologists separately, has provided us with a real-world view of these poor communication interactions.

During our presentation, we shared two video clips of interactions between oncology patients and their oncologists. Unfortunately, one can’t really call them conversations, as they are completely dominated by the oncologists. These videos helped to demonstrate some of what the patient has to deal with. The visits are wrought with emotion, and the oncologist not only dominates the interaction, but throws out medical jargon and technical terminology that even the brighter than average patient cannot understand.

Witnessing this, we asked ourselves a couple important questions:

“If today’s patient is more informed about their health overall, and cancer is far less stigmatized in today’s society, why isn’t the cancer patient having more of a voice? And, what does this say about the role of DTC in advancing the cancer conversation?”

To help us gain a better understanding, we conducted an online survey with our WPP partners at Lightspeed, and reached out to 100 people ages 18-65 who are either going through cancer treatment or have completed cancer treatment. We focused the survey mostly on people who had been diagnosed with breast cancer, lung cancer, or melanoma, as many of the DTC ads out today are focused on these topics; however, other cancer types were also included.

We learned that DTC contributes to a more level playing field. Seeing a DTC ad helps cancer patients become more comfortable and educated. It also supplements the research they are already doing, and provides a comfort level.

Over half of the respondents replied that they agree, or strongly agree that seeing a pharmaceutical ad for a cancer treatment reminds them that they’re not alone.

Our research also demonstrated that DTC supports a more common, better understood language about cancer. It helps provide patients with information in their own language. It also helps to identify that there are choices available so they can balance what they’re being told by their oncologists.

In addition, DTC helps improve overall feelings of trust for cancer patients. Those we surveyed told us they feel more informed, more comfortable with medical conversations, and less alone as a result of exposure to DTC advertising.

Trust is a topic that was of particular interest to us, so we dug deeper into this data. We found 84% of our survey respondents said they are extremely or very likely to trust their oncologist. And while pharmaceutical companies ranked the lowest when patients were asked about trusted sources of cancer treatment information, they did report that DTC advertising itself improves their trust in the specific product or brand that was advertised.

Regardless, it was not a surprise when 93% of patients surveyed said they have not asked for an oncology treatment by name. This is a consistent finding with our ethnographic research experiences across other categories.

In summary, cancer has become “Primetime” for a reason. At a high level,

  • Patients today expect to be informed
  • They demand information at their fingertips
  • They don’t want to be blindly led

What does the future of oncology DTC look like?

  1. We must continue to tap into and align with cultural values.
  2. We should look to be even more informative and balanced, not less.
  3. We need to find ways to connect with patients on their terms.

As DTC marketers, there is an incredible opportunity in front of us to help fuel an evolving and improved two-way conversation.

While patients will continue to look to and trust their oncologists and the cancer community for expertise and guidance, DTC can also continue to stimulate patient awareness and understanding, provide an often needed feeling of inclusion and support, and, thereby, support a more level playing field.

If you have questions or clients who you feel would benefit from knowing more, please reach out to Catherine Goss or Ashli Sherman.

 

Reference

1 – Manhattan Research, Google Consumer Study 2015 among online patients.

 

Catherine_Ashli_Ogilvy


April 25, 2018 0

If you’ve been asking hard questions about the data provided by your DTC and POC campaign partners, you’re not alone. Although the heightened scrutiny is new, the challenges aren’t. The good news is that trustworthy solutions are established, proven, and available.

Treatment decisions and research are guided by data that meets exacting standards for quality, reliability, and accuracy. The campaigns you use to reach patients should be no different. Take charge and build confidence in your marketing results by aiming for the gold standard in verifiable, trustworthy performance metrics and applying these standards to your brand messaging.

Use statistically valid matched-panel experimental design. Long before any of us learn the intricacies of marketing disciplines, we learn the fundamentals of any sound experiment: the test and control groups. Yet those principles are often overlooked when budgeting significant sums of money to reach patients with information that can significantly improve their quality of life. Get back to basics by working with partners that can demonstrate that the demographics and media exposure in both test and control groups are the same. Your partner should also isolate for seasonal and market factors, and measure results in weeks both pre- and post-campaign.

Ask for third-party validation that’s part of the campaign fabric, not a quick fix. The widespread industry focus on third-party validation is as welcome as it is overdue. But it should be part of your partner’s business model, not an afterthought, bandage, or public relations move. The independent third-party analyst should be working with timely sales data and presenting reports to clients in a timely manner. That means weeks, not months. And if the independent analyst hasn’t been working with your partner for years, it bears asking why.

Demand shorter waits for data and analysis. Understanding the health and success of your campaigns needs more than just raw data. It needs data in a timely manner, soon enough to be able to make sensible adjustments before seasonal effects and other market forces can overwhelm your ability to act. Yet delays of 45 to 60 days just to get a data snapshot are common among many campaign partners and data providers. The right partners have relationships with POC operators and data aggregators to make delivery a priority.

Get data that supports your comprehensive marketing mix analysis needs. As the range of DTC and POC outreach channels grows, it’s becoming increasingly important to follow the lead of other industries and conduct detailed marketing mix analysis. Ideally, you want to understand just how much each channel’s investment contributes to the overall success of your marketing plan. That’s harder to do if your data partners can’t provide detailed analysis of the periods before and after your campaign or can’t isolate for the effects of your other media investments. Work with your trusted providers to ensure that the proper metrics from their respective campaigns are incorporated into your marketing mix analysis template.

For tangible results, look at actual sales figures, not estimates. Because of concerns ranging from patient confidentiality to a lack of interactivity, many POC and DTC channels only allow results to be measured in broad strokes. Inferences and estimates, not hard conversions and sales, are the best you can get from broadcast or with in-clinic messaging. Invest some of your campaigns in channels that can deliver actual sales figures, not just assumptions and correlations. Partners that can analyze prescription sales data, obtained in cooperation with the largest retail pharmacy chains, can capture actual incremental script volume at the location or market level. It is more straightforward to attribute ROI to actual sales volume changes than to softer measures like ad recall or reach. And when you can isolate results at the individual store level, you get a much clearer picture of campaign lift than regional or nationwide trends can reveal.

Invest in POC campaigns with fully transparent implementation protocol. It’s tough to argue with the old international diplomacy adage “trust, but verify.” Partners should earn and maintain a level of trust that means you, the client, don’t feel the constant need to send secret shoppers to check every last rollout of every single campaign. But when verification is important, you want to be able to get answers as quickly and unobtrusively as possible. POC campaigns that reach into semi-private or off-limits areas, like clinic rooms, are cumbersome and difficult to verify. Campaigns in public spaces with growing importance as a hub for coordinated care, like the retail pharmacy, are much easier to verify. Ideally, your partner will provide signoff from its own field force, so you can confirm the date each new campaign launched at every location.

Improve the size of your data set by reaching more patients in more measurable locations. Studies show that a typical patient visits a pharmacy to purchase self-prescribed OTC products eight times more often than they visit a physician in clinic. And outcomes in the retail pharmacy setting are much easier to measure than in a stand-alone clinic. Increase your exposure there, and you increase the size and robustness of your data.

Make a habit out of granular analysis, especially with highly targeted campaigns. Fine-tuning campaigns down to a region or market lets you reinforce your presence where performance is already strong, and elevate it where your performance is weak. You can also use these campaigns to test how entrenched a dominant competitor is. These focused experiments should be measured as carefully as a national rollout, but the results should be kept in the proper context. A high-performing test can be used to model the rollout and expectations for a broader campaign.

Help your partners design reports around your clear, transparent goals. In the long run, partners gear the depth of their analysis to the demands of clients. Early DTC campaigns focused on recall, so data reflected that. As the demand for clearer ROI and more repeatable results grows, partners will shift to accommodate. The clearer you are about your analytics needs, the more the industry will shift to match.

This is a terrific inflection point for the POC and DTC marketing industry, an essential channel for strong patient communication. But it’s not a doom-and-gloom moment. If anything, the renewed emphasis on verifiable results, validated figures, and trustworthy insights is causing us all to be more mindful of the work we do and the impact it has. And that’s a powerful, tangible result in itself.

Rob Blazek


April 25, 2018 0

Point-of-Care media must take responsibility for its trust and accountability because patient health depends on it.

According to the CDC, American patients visited the doctor nearly 1 billion times in 2017 – over three trips per person. In many of those doctors’ offices across the United States, patients found educational materials to aid them in their heath care journey.  In fact, Point-of-Care media reaches not only physicians’ offices and clinics but pharmacies and retailers, offering patients and their families valuable information at salient moments of diagnosis and treatment.  Recent questions about the validity and transparency of Point-of-Care companies have challenged the efficacy of these programs and put this vital channel in jeopardy.

Since its inception, Point-of-Care has aimed to provide equitable access for patients, caregivers, and consumers to find valuable resources in a wide array of locations. This information is frequently provided free of charge and often accompanied by sponsor messages. Accompanying these resources, advertisers gain premium access to key consumer groups in targeted, turnkey settings. Consequently, it is imperative that this media channel be held to the same standards as any other mainstream channel. Trust and credibility are key attributes for brands and agencies to feel confident that precious advertising dollars are put to good use.  Without this confidence, marketers have no choice but to seek other locations for their campaigns, and the Point-of-Care channel will be lost. Such action would be devastating for the industry, but even more impactful for those it serves.

Patients are struggling like never before.  Faced with complex insurance requirements, ever-changing government health policies, and rising costs, consumers in the waiting rooms and pharmacies have more questions than any prior generation. To make matters worse, the well-being of the population in the United States continues to decline, driving additional people into the healthcare system and increased overall strain. The tales of overworked physicians, exasperated patients, and a structure in peril have been well documented. The healthcare journey can now feel more like a frontier expedition, riddled with anxiety, uncertainty, and fear.

While Point-of-Care media can’t eliminate all of those emotions, its role in educating patients can create systemic benefits that can ease stress on the entire process.  With access to a wide array of print and digital-based resources, patients can become more knowledgeable about symptoms and disease states and learn about appropriate treatments that may be available.  With this knowledge, doctor-patient conversations can be more targeted and efficient, focusing the physician’s limited time on the most pressing concerns for the patient. Information is then available at home for reinforcement, boosting the prospects of adherence, and pharmacies can act as valuable outposts to complement patient care. Equally important, caregivers can find invaluable resources to maintain the health of loved ones.

Patient education is a crucial step to improve patient outcomes. But in order to take advantage of those benefits, the industry must require accountability for those who work within this domain.  Educational resources must have value for the intended audience and provide information in a clear, responsible manner. As such, that information must be distributed according to a strategic, thoughtful plan. The availability and targeting of assets purchased by marketing partners must be achieved and validated with full compliance.

Sponsors deserve the trust and credibility that should come with any other purchase. Programs must be sold and executed as promised, with proof of performance.  Point-of-Care must establish clear standards that match those of other media channels, such as television, radio, or outdoor advertising.

Different from those channels, however, is that failure to provide such credibility at Point-of-Care would deprive patients of critical information when they need it most.  It is incumbent upon the Point-of-Care industry to improve its standard of excellence and demand accountability from within. Patient’s lives depend on it.

Mathew Reynders


April 25, 2018 1

New Data Indicates that Consumers Want Targeted Health Ads

It’s one of the conundrums we face as health marketers, that health is completely personal. Pain is subjective. Symptoms vary. My epilepsy is different. What works for one consumer doesn’t necessarily work for the other. Not only does personal biology vary from person to person, but so does psychology, circumstance, and irrational decision-making.

So it’s fortuitous that, as mass marketing dies slowly, there is an emerging and vast body of evidence that targeted and tailored marketing indeed works better. And a lot of people are doing a lot of smart thinking around getting the “right message to the right person at the right time.”

And yet, because we are the health industry, we’ve learned to be conservative, and we hamstring our progress. We put such a premium on health privacy that it blocks our ability to get really personal. I’m not talking about HIPAA, which is indeed sacred, but rather the judgment that subconsciously compels us to view targeted marketing as being too targeted, even intrusive. Surely, we think, people won’t want to know that I, brand marketer, know and care about their migraine.

But with data opening up so many possibilities to precisely target an n of 1, we need to understand how consumers really feel about targeted health advertising. Because by not getting up close and personal, we’re missing the opportunity to really help patients in need. So PulsePoint recently commissioned a third party to conduct some preliminary research that starts to peel back the layers on this issue. And here’s what we found:

How Consumers Feel About Targeted Health Ads: Top 10 Findings

  1. Relevant healthcare ads motivate consumers to act

This study confirms that consumers look to digital healthcare advertising, among a variety of sources, for their healthcare needs. As expected, consumers are most interested in the information they get from healthcare providers. However, healthcare ads are also a viable and trusted source of information, and a key driver of behavior.

  • 89% of consumers indicated that they would take action if they saw a relevant digital healthcare ad.
  • Only 11% who would not.
  1. Consumers are open to, and some even prefer, targeted advertising

Based on their belief in healthcare advertising as a resource, consumers are willing to engage on a more personal level.

  • 79% are open to receiving targeted medical / health advertising, as long as they consider the information relevant.
  • Furthermore, 54% prefer targeted digital healthcare ads.
  1. Consumers trust healthcare ads across the web, and will respond

While consumers can be skeptical about advertising in general, trust in digital healthcare advertising is evident.

  • Currently, 59% trust healthcare ads they see on the web.
  • At least 59% of consumers are likely to respond.
  1. Trust and responsiveness are higher for ads served in a health context

Consumer trust in and responsiveness to digital health ads increase further when ads are served within health-related articles. This effect is seen even when the health-related articles are on non-medical websites.

  • 69% of consumers trust healthcare ads within health-related articles, even on non-medical websites (up from 59% for ads anywhere on the web).
  • 67% say they would respond (vs. 59% for ads anywhere on the web).
  1. Health consumers want to be educated

Consumers indicated that they will respond to all types of healthcare ads, but are especially receptive to vehicles that promote learning.

  • 74% are likely to respond to an ad providing an opportunity to receive educational materials.
  • Two-thirds are likely to respond to an advertiser-sponsored article.
  1. Content and context matter; format doesn’t

Ad formats do not play a significant role in triggering action. The form of the ad is not overly important to consumers.

  • Six out of ten consumers will respond to any format, including videos, screen takeovers, traditional banners, and sponsorships.
  1. Consumers are most interested in their own health situation

Consumers want to see ads that are about their own personal health situation.

  • 72% of consumers want to see ads regarding products which may improve an existing condition.
  • 64% want to receive advertising that may improve their health.
  1. Consumers are open to ads for most conditions, even sensitive ones

Remarkably, consumers are comfortable receiving digital healthcare-related advertising even when the topic is of a sensitive nature.

  • 73% are open to receiving digital ads for less serious conditions such as seasonal allergies.
  • More than half are open to receiving digital ads pertaining to more private or sensitive conditions such as STDs.
  1. Consumers are willing to share personal data to improve health

Consumers are taking an active role in their personal health by leveraging technology – e.g., fitness trackers, blood pressure monitors, and smart scales – and are open to sharing the data they collect in order to improve their health.

  • Half of all consumers are open to sharing the data they collect in order to improve their health.
  1. Consumers are willing to share personal data to receive more targeted, relevant ads

Consumers value having a more relevant advertising experience with the goal of improving their health, and are willing to share personal health data to personalize the ads they receive.

  • 55% are open to sharing information collected via a smart device to receive ads specifically relevant to them.

The research also reinforced what we already know; that healthcare ads are a successful vehicle for educating and activating consumers.

  • 70% have learned about a healthcare issue or disease from seeing an ad.
  • 56% reported that a healthcare ad has impacted a healthcare-related decision they have.

As a result of a healthcare ad,

  • 68% have researched a condition online
  • 60% have researched drugs / drug brands online
  • 55% have modified their lifestyle / behavior
  • 52% have taken medicines or supplements

Where do we go from here?

No doubt, the stakes are enormously high in health. No one wants to end up on the home page of WSJ.com as the marketer who took personalized marketing too far. But nor do we want to be those who didn’t take it far enough. Consumers are clearly demonstrating their willingness to accept, and even contribute to, highly-targeted advertising to improve their health. Let’s start to learn how we can leverage data, insights, and technology to create more personalized and authentically meaningful advertising experiences for our consumers. Challenge your media agencies and your creative agencies. And let’s make better ads.

Research Methodology

This research was commissioned by PulsePoint and was conducted by the advertising and marketing technology research firm, Industry Index, in November 2017. Data highlighted in this article includes final, completed responses only, and does not include respondents who were disqualified at any point within the survey.

To achieve stated objectives:

  • Industry Index surveyed 1,000 consumers, geographically dispersed across the United States
  • Respondents were evenly split by gender to include 500 males and 500 females
  • All respondents must have visited any doctor within the past two years, and must currently use the internet at least three days per week (for more than email access alone) to have been considered eligible for participation in this research.

For more details about the research and its methodology, click here to read, Do consumers want targeted healthcare ads?, a blog post bylined by Industry Index EVP Matthew Thornton.

Chris Neuner


April 25, 2018 0

Chances are you already know that content marketing is important to reach the people that matter to your brand. Even more importantly, content marketing can help patients know that a treatment exists while giving them the opportunity to connect with each other in social platforms. This enables people to do something that no other part of the healthcare system provides: understanding what good health outcomes look like and how to get there.

Content marketing is increasingly significant as today’s consumers are actively avoiding ads. In just the next 24 months, the US will have more than 270 million video-on-demand subscribers: people who are willing to pay a monthly fee to watch.[i] This year alone, eMarketer estimates that more than one quarter of the country’s online users will be using ad blockers, growing at an annual rate of 16.2%.[ii] If that didn’t underscore the need for content marketing, consider that nearly half of all millennials online are currently skipping and blocking ads.

As brand marketers adjust to develop a content strategy that adapts to these consumer trends, they’re finding the world is fractured and complex. Gaining clarity of decision-making seems virtually impossible. The people important to your brand are practically anywhere. Social platforms are selling more conventional ads, but they only deliver metrics like ads and do not provide sharable content.

After a few years of analyzing how content performs through millions of engagements, we’ve seen some patterns emerge for how to create strategies that out-deliver most every other marketing method. And they’re more pragmatic than you think.

Connecting Advertising with Relationship Management

Advertising campaigns across mass media platforms are excellent methods to get the right people aware of your message in large numbers. They literally make a person aware of what the medication is, why a person might need it, and the aspirational moment of successful treatment. Anyone who says these ways of reaching audiences at scale don’t work is simply wrong.

The other widely used method to reach audiences is CRM (customer relationship management). When someone is ready to consider specific treatments, CRM can offer that person more specific information about the medicine and lead to some incredible ambassador programs for those actively on treatment.

But there’s a wide gulf between advertising methods and CRM. I like to call it the “cut to” of static marketing. When investing in just advertising and relationship management kinds of messaging, it’s as though the brand is saying that once the marketer concludes that you’re aware of the medication, then just cut to relationship management.

We know there are a lot of actions that must take place between the moment a person sees an ad and the time they become part of a relationship management stream. Content marketing provides a series of ways to help people get from one to the other.

Getting from Awareness to Relationship

Think about someone who has seen an ad that really resonates with them. They immediately identify with the story and the value proposition. Now what? How do they know what to do the next morning, the conversation to have with a partner, a family member, or a doctor? How do they know the steps to take so they can achieve the aspirational moment they have seen in your ad?

Or, say they understand the ad, but they are not motivated to take action because the reason a person seeks treatment in the ad to which they were exposed is not the same motivating factor that will drive them to take a specific action.

Content can offer a range of highly specific options for people so that taking action is as easy as possible, even when they have low motivation. One example is this post from the HealthySexual campaign. In an ad, from the perspective of the campaign, it only makes sense to say, “Talk to your partner about your history.” But as content, it is important to be highly specific to the behavior that must take place.[iii] People will find that approach far more valuable, using the content to take action, represent their own ideals, and enable generations of sharing.

Putting this content on to social platforms sparks people to comment with a wide range of perspectives, any one of which could be the “ah-hah” moment for a patient. At this point, content plus paid media has exposed your audience to something better than any single ad. It is presenting them with an array of specific actions that offer a practical “way in” provided by someone just like them.

On the relationship management side you can make content that takes time into account and helps to prompt a specific action, like relationship management, where you can specifically prompt a patient at the beginning of the day to put their medicine in their backpack, then at mealtime promote a post that reminds them to take the medicine.

In this sense, yes, content marketing efforts should overlap between advertising and relationship marketing. It’s also the easiest way of thinking about budgeting for content marketing. When someone becomes aware of a brand’s treatment, content marketing is there to help them understand how and why to take actions that help them. Then, as they are able to use that content to get closer to treatment, they are motivated and ready to join a relationship management program on their own terms.

So when you’re faced with the inevitable “do more with less” budget, content marketing should be an investment that comes from both existing advertising and CRM budgets. The good news is that both advertising and CRM will see dramatically increased performance, but with some key differences.

Driving Performance with Trust

It’s not always immediately obvious where the media efficiency lies in content marketing, especially if you’re placing ads on social platforms like Facebook lite and Twitter handleless ads. These are ad vehicles and not content vehicles. You will be able to compare them more directly to the way you are measuring advertising, and that’s it.

When you make the transition to investing in content that uses paid media rather than ads, shares will result. Those shares will drive media efficiency. In social channels, your audience doubles as both consumer of the content and the working media distributing the content, so the efficiency will come through the distribution and not only in the initial investment.

What’s best – and most difficult to measure in this case – is also the most treasured: trust. When a person uses the brand’s content to represent the way they feel about a topic, it’s not to a group of strangers. Every person in a social network represents new networks of people with whom they have some degree of credibility and trust. These kinds of connections and value shared between people can’t be bought or imitated by a company. Companies can only use paid media to introduce people to content they wouldn’t ordinarily have been exposed to.

You won’t see this widely written because when it’s done right, the results are significant and impact the way the brand is managed. I can say that in some cases, we’ve seen 50% return on investment on paid media spend and decreases in earned cost per engagement (eCPE) of 30%. What makes it difficult as a business case is that you won’t be able to know the true cost savings until you have calibrated spend, targeting, and content: exactly what pilot budgets are for.

On the CRM side, content marketing delivers far more qualified people, at a far higher rate, at much lower cost. One example is a social adherence program that reduced cost-per-touch by 90% when compared to the CRM stream itself, and 8 out of 10 patients surveyed said they were more adherent after they followed the campaign on that platform. In one case, content outperformed driving new CRM signups 76 to 1 over other digital advertising.

Change is never easy, especially when ads have largely worked the same way and been measured the same way for decades. But content is closer to both ads and relationship management than most people give it credit for. In fact, the great thing about effective content is that it’s the best of both.

Good content inspires people as they become aware of a treatment or a method to get to better health outcomes when they may not have many answers. But through storytelling with specific, behavioral actions as the foundation to content marketing, you are using your brand to help people find out how to take the steps they need to gain healthy solutions and relationships for life.

 

References

[i] Feldman, D. Forbes. Netflix Remains Ahead Of Amazon And Hulu With 128M Viewers Expected This Year. https://www.forbes.com/sites/danafeldman/2017/04/13/netflix-remains-ahead-of-amazon-and-hulu-with-128m-viewers-expected-this-year/#207b62ac216c

[ii] eMarketer Scales Back Estimates of Ad Blocking in the US. https://www.emarketer.com/Article/eMarketer-Scales-Back-Estimates-of-Ad-Blocking-US/1015243

[iii] HealthySexual Tumblr. http://healthysexual.tumblr.com/post/154767314982/break-the-ice-with-your-partner

Michael Leis


March 29, 2018 0

The FDA recently released “Drugs@FDA Express”, a mobile app that allows users to search for information about FDA-approved brand and generic prescriptions, OTC medications, and biological therapeutic products. The mobile app is a “light” version of the full website, with the app omitting letters and reviews – although the app’s homepage states this and includes a link to the website for “the complete version.”

Users of the free app can search by drug name, active ingredient, or application number. They can also view the last seven days of product approvals, as well as links to FDA web pages and FDA help and support (including the agency’s glossary, FAQs, and emailing the Division of Drug Information, FDA/CDER).

FDA Commissioner, Scott Gottlieb, MD, stated in the news release announcing the app: “Consumers are embracing digital health technologies to inform everyday decisions. From fitness trackers to mobile applications tracking insulin administration, these digital tools can empower consumers with a wealth of valuable health information. Advancing mobile apps that inform people about their health and medical choices represents a significant public health opportunity and is a high priority for the FDA. The FDA is continuously seeking ways to bring information to consumers in more accessible formats. Today, with the launch of the Drugs@FDA Express mobile app, we’re bringing the public important information about drugs in an easy-to-use, mobile format. We hope that by making this important health information more easily accessible we can help empower patients and providers in making their treatment decisions.”

The app is available for both Apple and Android devices.

admin